Literature DB >> 18792100

Test positivity cutoff level of a high risk human papillomavirus test could be increased in routine cervical cancer screening.

Laura Kotaniemi-Talonen1, Nea Malila, Pekka Nieminen, Ahti Anttila, Jussi Tarkkanen, Pekka Laurila, Matti Hakama.   

Abstract

We present data on test positivity, relative sensitivity, rates of detection and relative specificity for primary human papillomavirus (HPV) testing with different cutoff levels for test positivity, in comparison to conventional cytology. In 2003-2004, 18,438 women were screened primarily with Hybrid Capture 2 (HC 2) assay, a test for oncogenic HPV DNA, and 21,446 with conventional cytology within the organised screening programme in Finland. A cytological triage test was performed for the HPV positives. Women with cytology equal to low grade squamous intraepithelial lesion (LSIL) or worse were referred for colposcopy. The relative sensitivity measured as relative risk (RR) of any cervical intraepithelial neoplasia (CIN) or cancer was 1.58 for the HPV test at the relative light units (rlu) ratio cutoff 1.00, in comparison to cytology. With the cutoff 3.00, all CIN 2+ lesions were detected. With cutoff 10.00, 2 of the 22 CIN 3+ lesions were missed. Relative specificity for HPV screening for any CIN was 92.6% at cutoff 1.00, 94.6% at cutoff 3.00 and 96.3% at cutoff 10.00. For CIN 3+ specificity estimates for these cutoffs were 92.1%, 94.1% and 95.8%, respectively. Used for routine screening as the sole test, the HPV test cutoff can be increased from the level recommended for clinical use. With HC 2, the detection rate at rlu ratio cutoff 10.00 is still at the level of high-quality conventional screening. At that level, the false positive rate is reduced by about half and the specificity of the HPV test becomes equal to the average specificity of conventional cytology. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18792100     DOI: 10.1002/ijc.23839

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Human papillomavirus viral load expressed as relative light units (RLU) correlates with the presence and grade of preneoplastic lesions of the uterine cervix in atypical squamous cells of undetermined significance (ASCUS) cytology.

Authors:  M Origoni; G Carminati; S Rolla; M Clementi; M Sideri; M T Sandri; M Candiani
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-03-01       Impact factor: 3.267

2.  Performance of the Aptima high-risk human papillomavirus mRNA assay in a referral population in comparison with Hybrid Capture 2 and cytology.

Authors:  Andreas Clad; Miriam Reuschenbach; Johanna Weinschenk; Ruth Grote; Janina Rahmsdorf; Nikolaus Freudenberg
Journal:  J Clin Microbiol       Date:  2010-12-29       Impact factor: 5.948

3.  Comparison of Hybrid capture 2 testing at different thresholds with cytology as primary cervical screening test.

Authors:  D C Rijkaart; V M H Coupe; F J van Kemenade; D A M Heideman; A T Hesselink; W Verweij; L Rozendaal; R H Verheijen; P J Snijders; J Berkhof; C J L M Meijer
Journal:  Br J Cancer       Date:  2010-08-31       Impact factor: 7.640

4.  Incomplete follow-up of positive HPV tests: overview of randomised controlled trials on primary cervical screening.

Authors:  M Rebolj; E Lynge
Journal:  Br J Cancer       Date:  2010-07-13       Impact factor: 7.640

Review 5.  Human papillomavirus testing in primary cervical screening and the cut-off level for hybrid capture 2 tests: systematic review.

Authors:  Matejka Rebolj; Jesper Bonde; Sisse Helle Njor; Elsebeth Lynge
Journal:  BMJ       Date:  2011-05-23

6.  Clinical relevance of the borderline results of the Hybrid Capture 2 High-Risk HPV DNA assay with cervical samples collected in Specimen Transport Medium.

Authors:  Jerneja Varl; Urska Ivanus; Ziva Pohar Marinsek; Tine Jerman; Anja Ostrbenk Valencak; Mario Poljak; Veronika Kloboves Prevodnik
Journal:  Radiol Oncol       Date:  2019-09-24       Impact factor: 2.991

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.